The relatively lower values of skeletal muscle nitrate observed following supplementation, in individuals with PAD may be potentially due to a variety of factors including; lower muscle nNOS‐activity (Elrod et al., 2008); lower vascular eNOS‐activity; higher NO reduction by ROS; or reduced expression of membrane transport proteins, such as sialin (Dröge, 2003; Li et al., 2018; Yang et al., 2009). The gene discussed is SLC17A5; the disease is peripheral arterial disease.